Exit

Dark Matter Bio

Why Now. Why Us.

The invisible forces shaping the future of human health

10× compression
in discovery cycles
01

The Timing Window

Bioscience, compute, and capital have converged. The half-life between discovery and application is collapsing.

  • CRISPR evolved from editing to base editing to prime editing
  • AI-native drug discovery compresses timelines
  • First FDA approvals for true aging interventions
02

Data as a Sense Organ

Health becomes a live data problem. Continuous biomarkers replace episodic snapshots.

  • Wearables generating continuous physiological streams
  • Multi-omics panels becoming routine
  • Biological age vs chronological age measurable
03

Our Unfair Advantage

Trusted networks at the intersection of research, builders, and distribution partners who route breakthroughs to market.

  • Deep relationships with Stanford [1] & Cedars-Sinai [2]
  • Longevity influencer network with millions of followers
  • Cross-pollinating venture and operating experience
Our Differentiation

Why Dark Matter

Our Differentiation

Scientific depth, exclusive access, and tight focus on defensible longevity technologies

Competitive Advantages

Five Pillars of Differentiation

🧬 Scientific Expertise
🔬 Deal Flow
🧩 Jigsaw Portfolio
🌐 Network
🛡️ IP Protection
🧬

Deep Scientific Expertise

in longevity biology

  • Decades of experience across biology, data science, and company-building
  • Embedded in leading geroscience centers working to extend healthspan [1] [2]
  • Distinguish true mechanism-based therapies from superficial wellness products
  • Support portfolio companies with trial design, regulatory strategy, and biomarker selection
🔬

Proprietary Deal Flow

via Stanford [2] & Cedars-Sinai [5] partnerships

  • Early visibility into spin-outs, pilot projects, and translational teams [1]
  • Access to key investigators and clinical trial infrastructure [3] [6]
  • Co-design company formation around validated science and IP [4]
  • NIH-backed aging clinical trials and gerotherapeutics programs
🧩

Jigsaw Portfolio

Pieces that fit together into a bigger picture.

  • Portfolio companies that learn from, partner with, or become customers of each other—multiplying value across the fund
  • LPs seek whole-market answers to complex problems and large-scale opportunities; individual companies rarely deliver that alone—our portfolio, collectively, can
  • Deep domain expertise, innovator networks, and information flows let us see pieces connect before others do
  • Few firms combine both the sophisticated vision of the big picture and the tactical ability to execute —- we confidently do.
🌐

Longevity Leader Network

Ben Greenfield, Bryan Johnson, Peter Attia

  • Platforms reaching millions of longevity-focused consumers and clinicians
  • Real-world testing grounds with highly engaged, data-rich users
  • Credible distribution, education, and awareness channels
  • Direct feedback from athletes, biohackers, and prevention-oriented patients
🛡️

IP-Protected, Scalable Solutions

Focus on defensible platforms

  • Novel therapeutics targeting fundamental aging pathways [1]
  • Diagnostic, digital, and AI-driven tools for personalized interventions
  • Strong intellectual property moats and clear regulatory paths
  • Measurable impact on healthspan—clinically meaningful outcomes [2]
The Team

A Team That Speaks Both Lab and Late-Stage Capital

Our differentiation is not theoretical—it's embedded in who we are

Mark Moline

Mark Moline

Managing Partner

Translates scientific narratives into investment-grade theses.

Skinner Layne

Skinner Layne

Founding Partner

Builds structures that bridge scientific discovery with institutional LP expectations.

Michael Staton

Michael Staton

Venture Operations

Implements state-of-the-art infrastructure for venture capital.

Thomas Vu

Thomas Vu

Founding Partner

Scaling products from early validation to mass adoption.

Anthony Borquez

Anthony Borquez

Commercialization

Driving user acquisition, partnerships, and go-to-market execution.

Portfolio Construction

Fund Strategy

Portfolio construction designed for category-defining longevity outcomes

$100M Fund Size
10 Year Term
25 Target Investments
Economics

LP-GP Alignment

2% Management Fee Annual on committed capital
20-25% Carried Interest Performance fee, back-ended
Meaningful GP Commitment Personal capital alongside LPs
Capital Deployment

Stage Allocation

50%
30%
20%
Seed Series A/B Follow-ons

Seed (50%): Lead or co-lead in technical and scientific founding teams

Series A/B (30%): Scale capital into companies showing human data and traction

Follow-ons (20%): Systematic double-down into top decile outcomes

Geography

Geographic Focus

70% U.S. / Europe

Best-in-class research hubs with deep biotech talent and established exit markets

30% Rest of World

Opportunistic positions in Israel, Asia, and emerging innovation clusters

Investment Approach

Check Sizes & Follow-on Strategy

$2.75M–$3.0M Initial Check
10–15%+ Target Ownership
$5M–$10M Winner Reserves
Top 3-5 $5M–$10M+
Next 8-10 $3M–$5M
Remaining Pro-rata only
LP Value

How This Serves LPs

1

Balanced Diversification

~25 core positions across the longevity stack with meaningful concentration in winners

2

Stage Mix Advantage

Seed taps early entry pricing; A/B compounds into validated companies

3

Systematic Framework

Written reserve rules avoid emotional decisions, focusing on highest risk-adjusted MOIC

Institutional Grade

Venture Returns from the Longevity Ecosystem

Category-defining companies through critical inflection points